InflaRx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. 

CEO
Niels Christoph Riedemann
CEONiels Christoph Riedemann
Employees
74
Employees74
Headquarters
Jena, Thueringen
HeadquartersJena, Thueringen
Founded
2007
Founded2007
Employees
74
Employees74

IFRX Key Statistics

Market cap
65.34M
Market cap65.34M
Price-Earnings ratio
-0.92
Price-Earnings ratio-0.92
Dividend yield
Dividend yield
Average volume
405.70K
Average volume405.70K
High today
$1.01
High today$1.01
Low today
$0.935
Low today$0.935
Open price
$0.935
Open price$0.935
Volume
213.83K
Volume213.83K
52 Week high
$1.94
52 Week high$1.94
52 Week low
$0.7113
52 Week low$0.7113

Stock Snapshot

InflaRx(IFRX) stock is priced at $1.00, giving the company a market capitalization of 65.34M. It carries a P/E multiple of -0.92.

As of 2026-03-24, InflaRx(IFRX) stock has fluctuated between $0.94 and $1.01. The current price stands at $1.00, placing the stock +7.0% above today's low and -1.0% off the high.

InflaRx(IFRX) shares are trading with a volume of 213.83K, against a daily average of 405.7K.

During the past year, InflaRx(IFRX) stock moved between $0.71 at its lowest and $1.94 at its peak.

During the past year, InflaRx(IFRX) stock moved between $0.71 at its lowest and $1.94 at its peak.

IFRX News

TipRanks 4d
InflaRx price target lowered to $14 from $22 at Guggenheim

Guggenheim analyst Yatin Suneja lowered the firm’s price target on InflaRx (IFRX) to $14 from $22 and keeps a Buy rating on the shares. The firm continues to th...

Nasdaq 5d
InflaRx N.V. Reports Q4 Loss, Lags Revenue Estimates

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.09 p...

InflaRx N.V. Reports Q4 Loss, Lags Revenue Estimates
TipRanks 5d
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027

The latest update is out from InflaRx ( (IFRX) ). On March 19, 2026, InflaRx reported its full-year 2025 results and outlined a strategic pivot to focus on izi...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

More IFRX News

TipRanks 5d
InflaRx reports FY25 EPS vs. last year

Reports revenue EUR 29.3M vs. EUR 165.8M last year. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx (IFRX), said: “With the strong Phas...

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.